Media, News
New tumour destruction data for Prescient’s OmniCAR and CellPryme platforms
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR and CellPryme cell therapy platforms at the prestigious International Society…
Media, News
Cell Therapies presentations from ISCT
Prescient was pleased to present data on our cell therapies at the prestigious International Society of Cell & Gene Therapy (ISCT) conference in Paris in…
Media, News
Major milestones Prescient Therapeutics (ASX:PTX) eyes in 2023
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for multiple types of cancers. The company’s platform consists of targeted…